Clinical Trial Detail

NCT ID NCT02202746
Title A Study to Assess the Safety and Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGF Aberrant Metastatic Breast Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Clovis Oncology, Inc.
Indications

breast cancer

Therapies

Lucitanib

Age Groups: adult

Additional content available in CKB BOOST